Five things for pharma marketers to know: Tuesday, May 1, 2018

Share this content:

Fitbit is partnering with Google Cloud to make it easier for consumers to share health data with physicians. Information from the wearable could be combined with electronic medical records to help providers treat chronic conditions. (Bloomberg)

Regeneron Pharmaceuticals and Sanofi will slash the list price of Praluent, a cholesterol-lowering drug, for Express Scripts customers in exchange for access to patients. The drug, which debuted in 2015, was blocked by restrictions put in place by insurers and pharmacy benefit managers. (Forbes)


The National Association of Cannabis Businesses has proposed guidelines for cannabis marketing in the U.S. Taking cues from the alcohol and tobacco industries, the rules include a ban on unsubstantiated health claims and the stipulation that digital, TV, radio, and print ads should only be placed where no more than 15% of the audience is under 21. (MM&M)


Novo Nordisk has teamed up with a San Francisco startup to tie better medication adherence to lower medical costs for 10,000 patients with diabetes. For example, those who fill their prescriptions on time will receive lower co-payments. (pharmaphorum)


Bristol-Myers Squibb has pulled three late-stage clinical trials of its IDO1 inhibitor, which it acquired in 2015 for $800 million. In April, a late-stage trial that tested an IDO inhibitor from Incyte in combination with Merck's cancer treatment also failed. (Xconomy)


Share this content:
Scroll down to see the next article